Highly efficient R&D team and superior products with worldwide IP protection Targeting 3.5 years from discovery to IND Experienced in filling First Class New Drug IND & NDA in China Striving for fast market entry and price protection
With multiple and flexible business model system adapting to different market needs and regulations.
Joint venture
(HEC model)
Local manufacturing & marketing
(ZheJiang Medicine model)
Drug product supply
(Carnot)
Antibiotic resistance is one of the threats in public health. New generation antibiotic will satisfy the unmet medical needs. Non-fluorinated quinolone, nemonoxacin, has been out-licensed to Asia, East Europe and Central, South America, Canada, New Zealand, Australia and South Korea.
Based in Seoul, S. Korea, GPCR Therapeutics is a world leader in the field of GPCR heteromer science and has proprietary expertise and technology applicable to the development of this class of anti-cancer targets. CXCR4 antagonism is a well-accepted avenue towards cancer therapy and GPCR Therapeutics is well experienced and possesses the necessary know-how to develop Burixafor in the oncology field.
A pharmaceutical enterprise focuses on drug discovery, manufacturing and marketing in the field of antiviral, endocrine, metabolic and cardiovascular disease. TaiGen signed a Memorandum of Understanding with YiChang HEC ChangJiang Pharmaceutical Co. Ltd to collaborate in the research and development of a novel all-oral interferon-free treatment for chronic hepatitis C virus (HCV) infection.
In June of 2012, TaiGen and Zhejiang Medicine Company, Limited ("ZMC") signed an exclusive agreement to manufacture and commercialize nemonoxacin, a novel broad-spectrum antibiotic, in China (excluding Hong Kong, and Macau). ZMC is a leading pharmaceutical company in China specializing in sales and distribution of pharmaceuticals and manufacturing of active pharmaceutical ingredients (vitamins and antibiotics). ZMC is a leader in the Chinese antibiotic market with levofloxacin, vancomycin, and teicoplanin in the product line. In addition to pharmaceuticals sales, ZMC is also known for its manufacturing quality. Its vancomycin active pharmaceutical ingredient has obtained GMP qualification from US Food and Drug Administration (FDA) and exported to western countries.
R-Pharm is a leading Russian pharmaceutical company with commercial operations in Russian Federation, CIS, and Turkey. In 2013, it has over 2800 employees with sales revenue of US$1.8 billion. Key business areas of R-Pharm include manufacturing, sales and marketing of prescription drugs, laboratory diagnostics, medical equipment, and venture investment.
Carnot was born in 1941 with the aim of developing pharmaceutical products. From its beginnings, managers established processes of excellence, hiring talented people who contributed to creating a company whose success is based on its strength, its values and its ability to adapt over more than seven decades. Being an entrepreneurial company, Carnot is capable of attracting and retaining talent to generate innovative products and services, in specialized niches in national and international markets, based on its own technology.
Academia Sinica, the most prestigious research institute in Taiwan has its campus within close proximity to TaiGen. Beginning in 2003, TaiGen has signed several collaborative agreements with the x-ray crystallography group at Academia Sinica for its drug discovery programs in antiviral and cancer fields. Under these agreements, Academia Sinica is responsible for developing the x-ray crystallography of drug lead/target protein complexes. The two parties have established an interactive and efficient collaboration structure; TaiGen provides funding for the research, while Academia Sinica in turn is entitled to receive payments when products from the collaboration are launched in the market.
In the summer of 2002, TaiGen signed a collaborative agreement with Chang Gung Memorial Hospital (CGMH), the largest private hospital in Taiwan. Under the agreement, CGMH will make available to TaiGen hepatitis and cirrhotic liver tumor tissues from 7,000 cancer patients. TaiGen will conduct gene expressing profiling of these diseased tissues for drug target selection and validation. In 2004, TaiGen signed a second collaborative agreement with the hospital to conduct HCV drug screening by employing an in-vitro viral replication system developed by investigators at the hospital.